INmune Bio Inc reports results for the quarter ended in December - Earnings Summary

Inmune Bio

28/03/2024 21:02

* INmune Bio Inc  INMB.OQ  reported a quarterly adjusted
loss
of 47 cents​​ per share for the quarter ended in December, lower
than the same quarter last year, when the company reported EPS
of -32 cents.  The mean expectation of two analysts for the
quarter was for a loss of 44 cents per share. Wall Street
expected results to range from -53 cents to -35 cents per share.
    * Revenue fell 71.1% to $28.00 thousand from a year ago;
analysts
expected $43.00 thousand. 
    * INmune Bio Inc's reported EPS for the quarter was a loss
of 47
cents​.
    * The company reported a quarterly loss of $8.41 million.
    * INmune Bio Inc shares had risen by 3.3% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for INmune Bio
Inc is
$21.00 

This summary was machine generated from LSEG data March 28 at
09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.44          -0.47          Missed
 Sep. 30 2023      -0.39          -0.48          Missed
 Jun. 30 2023      -0.40          -0.36          Beat
 Mar. 31 2023      -0.02          -0.36          Missed